KSHB: New developments in metastatic breast cancer treatment, research

October 21, 2019

New research shows exciting advancements in the treatment of metastatic breast cancer.

KSHB's Cynthia Newsome, who announced her own battle with metastatic breast cancer earlier this year, interviewed Dr. Timothy Pluard, medical director and oncologist with Saint Luke's Hospital Koontz Center for Advanced Breast Cancer, about the latest developments for Breast Cancer Awareness Month.

One of which was a recent clinical trial for a new HER2+ metastatic breast cancer drug. The new drug, called Tucatinib, showed improvements in overall survival and worked in patients with brain metastases. Saint Luke's was one of the sites participating in the trial.

"It emphasizes the importance of clinical trials because all of these advances come through clinical trials, which is something we've very focused on at the Koontz Center," Dr. Pluard said.

Watch the full interview below.

Related Content

Thumbnail
Kansas City Business Journal: Saint Luke's, Garmin, TeraCrunch Partner on Cancer Study Using Wearable
Saint Luke's Cancer Institute is partnering with Garmin Ltd. and TeraCrunch on a wearable study that combines health care, consumer electronics, and artificial intelligence for advanced cancer patients.
Thumbnail
KMBC: Clinical Trial at Saint Luke's Cancer Institute Shows Promising Results for New Breast Cancer Drug
A recent clinical trial has shown promising results for a new treatment option for HER2 breast cancer. KMBC talked to Dr. Tim Pluard about the local results.
Thumbnail
KCTV: Saint Luke's High-Risk Breast Clinic
Saint Luke's High-Risk Breast Clinic allows women with a higher chance of developing breast cancer to be closely monitored. Dr. Ruby Meierotto shared tips for reducing your risk on Better Kansas City.